Business Segments · Stock-Based Comp
Business Segments — Stock-Based Comp
Roivant Sciences Business Segments — Stock-Based Comp decreased by 20.0% to $69.52M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 5.8%, from $73.84M to $69.52M. Over 2 years (FY 2023 to FY 2025), Business Segments — Stock-Based Comp shows an upward trend with a 38.8% CAGR.
Analysis
StatementSegment
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ2 2023
Last reportedQ1 2026
Rolls up toCompensation and benefits
How to read this metric
High levels may indicate aggressive talent investment or dilution, while low levels may suggest cost control.
Detailed definition
This represents the non-cash expense recognized for equity-based awards granted to employees within a specific business...
Peer comparison
Standard metric for evaluating compensation structures in high-growth biotech companies.
Metric ID:
roiv_segment_reportable_segment_share_based_compensationHistorical Data
12 periods
| Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $38.72M | $38.72M | $38.72M | $38.72M | $36.84M | $59.44M | $69.39M | $73.84M | $71.08M | $70.83M | $86.87M | $69.52M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -4.8% | +61.4% | +16.7% | +6.4% | -3.7% | -0.4% | +22.7% | -20.0% |
| YoY Change | — | — | — | — | -4.8% | +53.5% | +79.2% | +90.7% | +92.9% | +19.1% | +25.2% | -5.8% |
Range$36.84M – $86.87M
CAGR+23.7%
Avg YoY Growth+43.8%
Median YoY Growth+39.4%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Roivant Sciences's business segments — stock-based comp?
- Roivant Sciences (ROIV) reported business segments — stock-based comp of $69.52M in Q1 2026.
- How has Roivant Sciences's business segments — stock-based comp changed year-over-year?
- Roivant Sciences's business segments — stock-based comp decreased by 5.8% year-over-year, from $73.84M to $69.52M.
- What is the long-term trend for Roivant Sciences's business segments — stock-based comp?
- Over 2 years (2023 to 2025), Roivant Sciences's business segments — stock-based comp has grown at a 38.8% compound annual growth rate (CAGR), from $154.87M to $298.30M.
- What does business segments — stock-based comp mean?
- The expense related to stock-based compensation for segment employees.